Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Dec 26;23(2):171–181. doi: 10.1007/s11102-019-01020-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — Proportions of patients achieving a hormonal control (defined as GH ≤ 2.5 µg/L and IGF-1 levels within normal ranges at LVA) and b tight hormonal control (defined as GH < 1.0 µg/L and IGF-1 levels within normal ranges at LVA), at LVA according to baseline GH and IGF-1 levels. GH growth hormone, IGF-1 insulin-like growth factor-1, LVA last post-baseline value available. Patients with baseline IGF-1 levels between 380 and < 740% ULN were grouped together. Of the two patients who achieved tight hormonal control at LVA, one patient had IGF-1 levels between 460 and 500% ULN, and the other between 540 and 580% ULN. Data are from the intention-to-treat population for patients with LVA data (n = 88)